November 28, 2007

Genetics of melanoma tumorigenesis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Melanoma therapy is moving away from combinatorial approaches and towards newer targeted strategies. With the identification of mutations in various RAS pathway genes, there are now tremendous opportunities to bring inhibitors of RAS signalling to the clinical arena.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Singh et al. (Wed,) studied this question.

synapsesocial.com/papers/6a22d2f24af801cf29604e09 https://doi.org/https://doi.org/10.1111/j.1365-2133.2007.08316.x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Retention of theCDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma1998 · 42 citations
2Molecular Basis of Human Piebaldism1994 · 130 citations
3Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.2000 · 370 citations
4Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines1998 · 237 citations
5Loss of c-kit expression in cultured melanoma cells.1992 · 147 citations

Preguntar a la IA

Me gusta

Guardar